1. Home
  2. NIVF vs MYNZ Comparison

NIVF vs MYNZ Comparison

Compare NIVF & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NIVF
  • MYNZ
  • Stock Information
  • Founded
  • NIVF 2011
  • MYNZ 2021
  • Country
  • NIVF Thailand
  • MYNZ Germany
  • Employees
  • NIVF N/A
  • MYNZ N/A
  • Industry
  • NIVF
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • NIVF
  • MYNZ Health Care
  • Exchange
  • NIVF NYSE
  • MYNZ Nasdaq
  • Market Cap
  • NIVF 9.8M
  • MYNZ 9.8M
  • IPO Year
  • NIVF N/A
  • MYNZ 2021
  • Fundamental
  • Price
  • NIVF $0.92
  • MYNZ $0.35
  • Analyst Decision
  • NIVF
  • MYNZ Buy
  • Analyst Count
  • NIVF 0
  • MYNZ 2
  • Target Price
  • NIVF N/A
  • MYNZ $3.00
  • AVG Volume (30 Days)
  • NIVF 323.1K
  • MYNZ 1.4M
  • Earning Date
  • NIVF 08-16-2024
  • MYNZ 08-13-2024
  • Dividend Yield
  • NIVF N/A
  • MYNZ N/A
  • EPS Growth
  • NIVF N/A
  • MYNZ N/A
  • EPS
  • NIVF N/A
  • MYNZ N/A
  • Revenue
  • NIVF N/A
  • MYNZ $895,479.00
  • Revenue This Year
  • NIVF N/A
  • MYNZ $67.40
  • Revenue Next Year
  • NIVF N/A
  • MYNZ $191.13
  • P/E Ratio
  • NIVF N/A
  • MYNZ N/A
  • Revenue Growth
  • NIVF N/A
  • MYNZ 69.00
  • 52 Week Low
  • NIVF $0.64
  • MYNZ $0.32
  • 52 Week High
  • NIVF $2.95
  • MYNZ $4.71
  • Technical
  • Relative Strength Index (RSI)
  • NIVF 39.18
  • MYNZ 37.39
  • Support Level
  • NIVF $0.90
  • MYNZ $0.39
  • Resistance Level
  • NIVF $1.25
  • MYNZ $0.46
  • Average True Range (ATR)
  • NIVF 0.08
  • MYNZ 0.07
  • MACD
  • NIVF 0.01
  • MYNZ 0.01
  • Stochastic Oscillator
  • NIVF 5.74
  • MYNZ 13.88

About NIVF NEWGENIVF GROUP LIMITED

NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Share on Social Networks: